

## Pharmaceutical Legislation and Guidance update

**NFS, Oslo, Thursday 21 May 2024**

Time	Session No.	Content
08:30 – 09:00		Registration and Welcome
09.00 – 09.10	1	Introduction and Objectives
09.10 – 09.45	2	Global changes: <ul style="list-style-type: none"> <li>• Artificial Intelligence (AI)</li> <li>• Decentralised Manufacturing</li> </ul>
09.45 – 10.30	2	Changes to EU Legislation and Guidance: <ul style="list-style-type: none"> <li>• New Human commercial medicines Directive and Regulation</li> <li>• Veterinary medicines GMP legislation</li> <li>• New Variations guideline</li> <li>• Propose legislation for Biotech and Critical medicines</li> <li>• Regulation 2025/40 for Packaging</li> </ul>
10.15 – 10.30		<i>Refreshment Break</i>
10.30 – 11.30	3	Changes to EU GMP Guidance <ul style="list-style-type: none"> <li>• Titanium Dioxide (TiO<sub>2</sub>) in Medicinal Products</li> <li>• European Pharmacopoeia changes</li> <li>• Revision of GMP Chapters 1 and 4</li> <li>• Revision of GMP Annexes 3, 4, 5 11 &amp; 15</li> <li>• EFPIA foreign inspections survey</li> </ul>
11.30 -12.30		<i>Lunch</i>
12.30 – 13.00		EU/EEA – UK Supply Chains
13.00 – 13.45		ICH and other International Changes <ul style="list-style-type: none"> <li>• ICH organisation; new members and observers</li> <li>• Recent draft and final guidance: M4Q(R2), M7, Q1/Q5C, Q3E,</li> <li>• Other recent publications from PIC/S, WHO, ICMRA, IPEC, etc.</li> </ul> New African Medicines Agency
13.45 – 14.30	6	Changes to USA Legislation and Guidance <ul style="list-style-type: none"> <li>• FDA management changes</li> <li>• OPQ State of Pharmaceutical Quality report</li> <li>• QMM update</li> <li>• Benzene contamination</li> <li>• New Final and Draft Guidance for Industry</li> </ul>

Time	Session No.	Content
14.30 – 14.45		<i>Break</i>
14.45 – 15.30	7	Quality Culture and its Impact on the PQS
15.30 – 16.00	8	Teamwork: Are we ready for these changes?
16.00		Final questions, Conclusion and Close